Live
CellGenetic variation reveals a homeotic long noncoding RNA that modulates human hematopoietic stem cells10x Genomics BlogDoes Atera’s New Spatial Biology Platform Change The Bull Case For 10x Genomics (TXG)? - simplywall.stEndpoints NewsBristol Myers’ pivotal year; Should AI be swinging bigger?; and moreEli LillyWhy Eli Lilly (LLY) Is Up 9.0% After Q1 Beat And Foundayo GLP‑1 Launch - And What's Next - simplywall.stWuXi BiologicsWuXi Biologics Advances Global Sustainability Strategy With 2025 ESG Report - BioPharma APACNovo NordiskFDA Proposal Could Support Novo Nordisk GLP‑1 Exclusivity And Valuation - simplywall.stAmgenBiopharma bites: Novo rebrands Rybelsus as the Ozempic pill, and Amgen trims its pipeline - FirstWord PharmaSamsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - lokmattimes.comSamsung BiologicsSamsung Biologics union continues strike regarding wages, other issues - Korea JoongAng DailySamsung BiologicsUnionized workers of Samsung Biologics continue strike for 2nd day - The Korea HeraldBoston ScientificAssessing Boston Scientific’s Valuation As Lower Guidance Weighs On Sentiment After Strong Q1 Results - simplywall.stLab-DirectCardiovascular Pacing and ICD Leads Price in Northern America - Market Insights - IndexBox
Agilent Mar 18, 2026

Agilent’s $950m Biocare buy: The ‘aligned’ asset for pathology innovation - BioXconomy

Agilent’s $950m Biocare buy: The ‘aligned’ asset for pathology innovation - BioXconomy

Original
Body unavailable. Use the original source.